As an outpatient psychiatric mental health nurse practitioner, should I refer a patient to a ketamine treatment program (intravenous infusion or intranasal esketamine) rather than administer ketamine myself?

Ketamine Referral for Outpatient PMHNPs

Yes, as an outpatient PMHNP, you should refer patients to specialized ketamine treatment programs rather than administering ketamine yourself, particularly for IV ketamine which requires specialized monitoring infrastructure, or to REMS-certified facilities for intranasal esketamine.

Regulatory and Safety Requirements

Intranasal Esketamine (Spravato)

• Esketamine requires REMS certification and mandatory 2-hour post-treatment monitoring in a certified healthcare setting 1, 2
• The FDA mandates administration under direct medical supervision with structured monitoring protocols 3, 4
• You cannot prescribe esketamine for self-administration at home; it must be given in a REMS-certified facility 3

Intravenous Ketamine

• IV ketamine at the standard dose of 0.5 mg/kg infused over 40 minutes requires appropriate monitoring equipment and trained staff to manage potential adverse effects including dissociation, hypertension, and psychotomimetic symptoms 1, 2
• While one psychiatric hospital demonstrated feasibility of a psychiatry-only team administering IV ketamine without anesthesia collaboration 5, this was in an acute inpatient psychiatric facility with full medical infrastructure, not an outpatient office setting
• The FDA labeling for IV ketamine does not specify outpatient psychiatric office administration as a standard setting 6

Clinical Practice Models

Appropriate Referral Settings

• Specialized ketamine clinics with proper monitoring capabilities are the standard of care for both IV ketamine and intranasal esketamine 1, 4
• These facilities have:
  • REMS certification for esketamine 3
  • Cardiovascular monitoring equipment 2
  • Staff trained in managing dissociative and psychotomimetic effects 1
  • Post-treatment observation areas for the mandatory 2-hour monitoring period 1, 3

Alternative Considerations

• Non-parenteral formulations (oral, sublingual, intranasal racemic ketamine) may be prescribed for home use in select cases by experienced clinicians, though evidence is limited 7
• This approach requires careful patient selection, structured safety monitoring frameworks, and assessment of misuse risk similar to prescribing stimulants or benzodiazepines 7, 8
• However, this remains off-label and requires significant clinical experience with ketamine prescribing 7

Patient Selection Criteria for Referral

Before referring, confirm the patient meets treatment criteria:

• At least 2 failed adequate antidepressant trials (4-6 weeks at therapeutic doses) to establish treatment-resistant depression 1
• Moderately severe depression on standardized rating scales 1
• For bipolar depression, concurrent mood stabilizer therapy (lithium or valproate) to mitigate manic switch risk 1

Safety Monitoring Requirements

Why Specialized Settings Are Necessary

• Psychotomimetic effects occur in approximately 20% of patients (hallucinations) and 12% (nightmares) at standard dosing 1, 2
• Cardiovascular effects include significant heart rate increases (>10 bpm) requiring monitoring 3
• Dissociative symptoms peak during and immediately after administration, necessitating supervised observation 1, 4

Post-Treatment Protocols

• Patients cannot drive or operate machinery for 24 hours after ketamine administration 6
• The 2-hour mandatory monitoring period for esketamine specifically addresses these safety concerns 1, 3

Common Pitfalls to Avoid

• Do not attempt to administer IV ketamine in a standard outpatient psychiatric office without appropriate medical monitoring equipment and trained staff 1, 5
• Do not prescribe esketamine for patient self-administration—this violates REMS requirements 3, 4
• Do not refer patients who have not failed at least 2 adequate antidepressant trials, as this does not meet criteria for treatment-resistant depression 1
• Ensure bipolar patients are on mood stabilizers before ketamine referral to prevent manic switching 1

Treatment Expectations to Communicate

• Antisuicidal effects begin within 40 minutes, with antidepressant effects persisting 2-3 days after single infusion 1, 2
• Standard induction involves twice weekly treatments for 4-6 total infusions 1
• Response is defined as ≥50% reduction in depressive symptoms at 24 hours post-infusion 1
• Maintenance frequency should be determined by monitoring for symptom return, typically 2-7 days after single infusion 1